Skip to content
Search

Latest Stories

Tim Wentforth named as Boots parent WBA’s new CEO

Walgreens Boots Alliance, Boots UK’s parent company, has appointed Tim Wentforth as its new CEO, effective on 23 October.

He joined WBA at a pivotal time when the company plans to downsize the business while driving execution and creating greater value for employees, patients, customers and shareholders.


Wentforth replaced Rosalind Brewer, who stepped down on 1 September, after two years at the helm.

He joined from Evernorth, Cigna’s health services organisation based in Connecticut, where he served as its founding CEO.

Prior to Cigna, he also held top roles in companies including specialty pharmacy company Accredo and pharmacy benefit manager Express Scripts.

“He is an accomplished and respected leader with profound expertise in the payer and pharmacy space as well as supply chain, IT and Human Resources,” said Stefano Pessina, Executive Chairman, WBA.

“We are confident he is the right person to lead WBA’s next phase of growth into a customer-centric healthcare company.”

WBA shelved its plan to sell Boots in June 2022, citing difficulties for potential buyers in raising necessary funds due to financial market instability.

At present, there is widespread speculation about WBA's second attempt to divest its UK assets as part of its ongoing efforts to tight-size the company.

WBA’s goal is to be the independent partner of choice, not just in pharmacy but also in healthcare services where it can improve healthcare, lower costs, and help patients, the statement added.

In July, Boots announced that it is moving forward with its plan to close 300 stores in the UK, despite significant sales growth in the quarterly results.

The company achieved robust quarterly results, with retail sales climbing by 13.4 percent and a ninth consecutive quarter of market share growth.

“WBA has a differentiated model with the power to build on the company’s pharmacy strength and trusted brand to evolve healthcare delivery,” Wentforth said.

“I believe in WBA’s vision to be the leading partner in reimagining local healthcare and wellbeing for all.”

“I’ve spent my career working to improve the health of the patients we’ve served,” he added.

"I believe WBA is well positioned to deliver more personalised, coordinated care and achieve better outcomes at a lower cost.”

“I fully recognise the challenges that health plans, healthcare providers, pharmacies and retailers are confronting today and am confident that WBA and its customer and patient-focused teams can seize the opportunities of a dynamic marketplace and be the partner of choice,” he further said.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less